Navigation Links
Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June
Date:5/30/2017

TEL AVIV, Israel, May 30, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, today announced that the Company's management will present a company overview at three upcoming scientific and investor conferences in June:

The 7th Annual LD Micro Invitational:


Date:                    

Wednesday, June 7th, 2017Time:                    

2:30 PM PST Location:             

Luxe Sunset Boulevard Hotel, Los Angeles, CaliforniaPresenter:         

Josh Blacher, Chief Financial Officer

The 2017 Marcum MicroCap Conference:

Date:                    

Thursday, June 15th, 2017Time:                    

10:30 AM ESTLocation:             

Grand Hyatt New YorkPresenter:         

Josh Blacher, Chief Financial Officer

The 27th Annual ICRS Symposium on the Cannabinoids:

Date:                    

June 22nd – 27th, 2017Venue:                               

Poster PresentationLocation:             

Le Centre Sheraton, Montréal, CanadaPresenter:         

Dr. Elran Haber, Chief Executive Officer and Dr. Adi Zuloff-Shani, Chief Technology Officer

About Therapix Biosciences:Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets to the treatment of Tourette's syndrome; and THX-ULD01 targets the high-value and under-served market of mild cognitive impairments. Please visit our website for more information at www.therapixbio.com.

For further information: Investor Contact: Josh Blacher, CFO, Therapix Biosciences, josh@therapixbio.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therapix-biosciences-to-present-at-upcoming-scientific-and-investor-conferences-in-june-300465279.html


'/>"/>
SOURCE Therapix Biosciences Ltd
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Therapix Biosciences Ltd. Announces Full Exercise of Underwriters Over-Allotment Option
2. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
3. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
4. Therapix Biosciences Provides Portfolio Update
5. The Israeli Pharma Company Therapix, is Joined by Five Internationally Renowned Experts, From Israel and the World, in the Field of Psychiatry and Tourette
6. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
7. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
8. Pressure BioSciences, Inc. Discusses Research Market, Goals and Milestones for First Half of 2017 in New SNNLive Video Interview with StockNewsNow.com
9. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
10. How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma
11. Hope Biosciences Acquires Worldwide Rights To Novel MERTK/AXL Inhibitor From NeoPharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
(Date:5/30/2017)... May 30, 2017 Therapix Biosciences Ltd. (Nasdaq: ... in the development of cannabinoid-based drugs, today announced ... overview at three upcoming scientific and investor conferences ... Micro Invitational: ... Date:                     Wednesday, ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and veteran ... the JFK Virgin Atlantic lounge. , Bensko is no stranger to the plight ... Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, her riveting ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted ... has come up with a proprietary technique that he calls the AuraLyft ... dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows , ... society in 11 countries across the Middle East and South Asia to embark on ... knowledge and ideas with the leading minds in their fields. , For the ...
Breaking Medicine News(10 mins):